1 / 17

Francis Hornicek, Laura MacConail, Levi Garraway, David Harmon,, Zhenfeng Duan

HIGH-THROUGHPUT MUTATION PROFILING OF OSTEOSARCOMA PRIMARY TUMORS AND CELL LINES IDENTIFIES NEW MUTATIONS IN PREVIOUSLY UNASSOCIATED ONCOGENES AND TUMOR SUPRESSOR GENES. Francis Hornicek, Laura MacConail, Levi Garraway, David Harmon,, Zhenfeng Duan. Edwin Choy MD PhD. Disclosures. none.

jolanta-dbrowski
Download Presentation

Francis Hornicek, Laura MacConail, Levi Garraway, David Harmon,, Zhenfeng Duan

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIGH-THROUGHPUT MUTATION PROFILING OF OSTEOSARCOMA PRIMARY TUMORS AND CELL LINES IDENTIFIES NEW MUTATIONS IN PREVIOUSLY UNASSOCIATED ONCOGENES AND TUMOR SUPRESSOR GENES Francis Hornicek, Laura MacConail, Levi Garraway, David Harmon,, Zhenfeng Duan Edwin Choy MD PhD

  2. Disclosures none

  3. Arndt and Crist 341 (5): 342,  July 29, 1999

  4. McDermott and Settleman, JCO, 2009

  5. Gene Amplification Point mutation Translocation

  6. What we did • We designed primers and genotyping assays using MALDI-TOF (matrix-assisted laser desorption/ionization-time of flight mass spectrometer; Sequonom iPLEX Genotyping) • Systematically characterize 1057 mutations in 108 genes across 100 osteosarcoma tumor samples and cell lines.

  7. What we did not do • Whole gene sequencing • Copy number analysis • RNA expression • microRNA sequencing • Translocation analysis • SNP analysis • Germ-line mutation testing

  8. Tarkkanen, Canc Res 1995

  9. Results • 108 genes were analyzed using iPLEX Genotyping. • Initially observed 19 mutations in 11 genes in at least one osteosarcoma sample • To validate these results, we retested all 19 mutations using hME Genotyping • confirmed 15 mutations in 8 genes

  10. Genes Analyzed • PTPN11 • IGF1R • NOTCH1 • PTEN • RB1 • SRC • EPHA1 • NF1 • CEBPA • CTNNB1 • C-MYC • FLT3 • GATA1 • TP53 • VHL • ALK • LRP1B • EPHA3 • TFDP1 • PDPK1 • STK11 • MINK1 • AKT • ABL1 • ADAMTSL3 • AML1/RUNX1 • APC • CDKN2A • ABL1 • BRAF • CDK4 • EGFR (166 mutations) • ERBB2 • ERB4 • FGFR • HRAS • NRAS • KRAS • JAK2 • KIT • PDGFRA • PIK3CA • RET

  11. Assay: OM_v2_1121 Samples: 50, 76 Gene: CDH1 Mutation: A617T

  12. Results We identified mutations in genes previously known to be altered in osteosarcomas: • p53 (R273H, Y163C, R273C, and Y163C) • RB1 (E137).

  13. Results We did not find canonical mutations in: • EGFR (166 mutations tested) • PDGF • KIT • BRAF • ALK • MET • RAS

  14. Results We also identified 7 mutations in 5 genes previously unimplicated in the pathogenesis of osteosarcomas: • PIK3CA (H1047R, E545K, and H701P) • KRas (G12S) • CUBN (I3189V) • CDH1/E-cadherin (A617T) • CTNNB1/B-catenin (N287S)

  15. Future Directions • Complete gene sequencing of all five novel genes. • Prospective genotyping for above novel mutations to better determine frequency • Explore efficacy of wnt, PI-3 Kinase, and farnesyltransferase inhibitors in osteosarcoma cell lines. • Further characterize osteosarcoma samples for downstream signaling elements, i.e. phosphorylated S6, TCF responsive elements, MAPKinase activation, etc.

  16. Acknowledgments Broad Institute of MIT and Harvard • Eric Lander • David Altshuler • Todd Golub MGH Sarcoma Molecular Biology Lab • Zhenfeng Duan • Francis Hornicek Dana Farber Cancer Institute • Levi Garraway • Laura MacConail Jennifer Hunter Yates Foundation • David Harmon

  17. Edwin Choy echoy@partners.org

More Related